Expressive Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Expressive Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$239K	Hold	1,416	–	–	0.23%	123
2026 Q1	$208K	Buy	+1,416	New	+$188K	0.2%	125

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Expressive Wealth's NBIX Position: Q2 2026 in Review

Expressive Wealth held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 1,416 shares worth $239K. The position accounts for 0.23% of the portfolio, ranked #123.

Expressive Wealth first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Expressive Wealth held 1,416 shares of Neurocrine Biosciences worth $239K as of Q2 2026.
Expressive Wealth left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up 0.23% of Expressive Wealth's portfolio in Q2 2026, its #123 holding.
Expressive Wealth first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Expressive Wealth's 13F filing for Q2 2026, filed 11 Aug 2026.